The resulting increased cancer risk reduces the therapeutic potential of Cdkn2a inhibition in contrast to senolytic treatment, which removes senescent cells and does not promote cancer development (Kirkland et al., 2017). The gene discussed is CDKN2A; the disease is cancer.